JP2025514382A5 - - Google Patents
Info
- Publication number
- JP2025514382A5 JP2025514382A5 JP2024563854A JP2024563854A JP2025514382A5 JP 2025514382 A5 JP2025514382 A5 JP 2025514382A5 JP 2024563854 A JP2024563854 A JP 2024563854A JP 2024563854 A JP2024563854 A JP 2024563854A JP 2025514382 A5 JP2025514382 A5 JP 2025514382A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- nr11r12
- alkynyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263336667P | 2022-04-29 | 2022-04-29 | |
| US63/336,667 | 2022-04-29 | ||
| PCT/IB2023/054494 WO2023209692A1 (en) | 2022-04-29 | 2023-04-29 | Inhibitors of rock2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514382A JP2025514382A (ja) | 2025-05-02 |
| JP2025514382A5 true JP2025514382A5 (enExample) | 2026-05-11 |
Family
ID=86604437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563854A Pending JP2025514382A (ja) | 2022-04-29 | 2023-04-29 | Ｒｏｃｋ２の阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250289807A1 (enExample) |
| EP (1) | EP4514466A1 (enExample) |
| JP (1) | JP2025514382A (enExample) |
| KR (1) | KR20250019030A (enExample) |
| CN (1) | CN119604496A (enExample) |
| AU (1) | AU2023262720A1 (enExample) |
| CA (1) | CA3250707A1 (enExample) |
| IL (1) | IL316616A (enExample) |
| WO (1) | WO2023209692A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026502949A (ja) | 2022-12-30 | 2026-01-27 | アヴィセンナ バイオサイエンシズ インコーポレイテッド | アザインドールｒｏｃｋ阻害剤 |
| IL327381A (en) | 2023-09-28 | 2026-05-01 | Graviton Pharmaceuticals B V | Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors |
| IL327385A (en) | 2023-09-29 | 2026-05-01 | Graviton Pharmaceuticals B V | ROCK2 inhibitors in the treatment of obesity |
| WO2026011129A1 (en) * | 2024-07-03 | 2026-01-08 | Avicenna Biosciences, Inc. | Azaindole rock inhibitors for the treatment of medical disorders |
| CN120204259B (zh) * | 2025-04-17 | 2025-11-18 | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | Rock2抑制剂及其在制备治疗胆管癌的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7311228B2 (ja) | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| JP7399848B2 (ja) * | 2017-09-01 | 2023-12-18 | カドモン コーポレイション，リミティド ライアビリティ カンパニー | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 |
-
2023
- 2023-04-29 US US18/861,104 patent/US20250289807A1/en active Pending
- 2023-04-29 JP JP2024563854A patent/JP2025514382A/ja active Pending
- 2023-04-29 IL IL316616A patent/IL316616A/en unknown
- 2023-04-29 CA CA3250707A patent/CA3250707A1/en active Pending
- 2023-04-29 EP EP23726610.1A patent/EP4514466A1/en active Pending
- 2023-04-29 AU AU2023262720A patent/AU2023262720A1/en active Pending
- 2023-04-29 CN CN202380050515.XA patent/CN119604496A/zh active Pending
- 2023-04-29 WO PCT/IB2023/054494 patent/WO2023209692A1/en not_active Ceased
- 2023-04-29 KR KR1020247038811A patent/KR20250019030A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538408A5 (enExample) | ||
| JP2024519496A5 (enExample) | ||
| CN110582489A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP2022544714A5 (enExample) | ||
| CN110573501A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP2019519476A5 (enExample) | ||
| JP2022507805A5 (enExample) | ||
| JP2022550640A5 (enExample) | ||
| JP2024517016A5 (enExample) | ||
| JP2022538301A5 (enExample) | ||
| JP2024167182A5 (enExample) | ||
| JP2020506899A5 (enExample) | ||
| JP2019514883A5 (enExample) | ||
| JP2018529745A5 (enExample) | ||
| JP2020535165A5 (enExample) | ||
| JP2018517731A5 (enExample) | ||
| JP2024541920A5 (enExample) | ||
| JP2011513476A5 (enExample) | ||
| JP2021513982A5 (enExample) | ||
| JP2022500469A5 (enExample) | ||
| JP2023533203A5 (enExample) | ||
| JP2019532054A5 (enExample) | ||
| JP2024517016A (ja) | Ｌｐａ受容体アンタゴニスト及びそれらの使用 | |
| WO2008117229A4 (en) | Muscarinic receptor antagonists | |
| JP2024505571A5 (enExample) |